Physician profile
Asra Batool
NPI 1912203829
$3,884.34
in general payments reported to CMS, 2019-2025
17 companies · $610 in 2025
The $610 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.73 · 2021: $88.65 · 2022: $972 · 2023: $1,318 · 2024: $852 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,757 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,757.15 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,613.96 | 2019-2025 | Rinvoq, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $302.03 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Gilead Sciences, INC. | $267.80 | 2021-2024 | |
| Ardelyx, INC. | $262.71 | 2023-2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $254.86 | 2023 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $160.72 | 2025 | Iqirvo |
| Medtronic, INC. | $157.68 | 2022 | |
| Fujifilm Healthcare Americas Corporation | $138.35 | 2025 | |
| Boston Scientific Corporation | $131.85 | 2023-2024 | Resolution 360 Clip |
| Conmed Corporation | $130.46 | 2022 | |
| Ferring Pharmaceuticals INC. | $118.78 | 2023 | Rebyota |
| Janssen Scientific Affairs, LLC | $89.60 | 2024 | |
| Genzyme Corporation | $80.57 | 2024-2025 | |
| Janssen Biotech, INC. | $76.82 | 2024-2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.43 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $21.95 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $17.77 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asra Batool listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.